A study of patients aged 70 or younger with high-risk prostate cancer found that black and Hispanic race was associated with a greater likelihood of receiving nondefinitive treatment, with patients experiencing poor outcomes as a result.
In a study, patients who had upper tract urothelial carcinoma with multifocal tumors had a 40% higher risk for urinary bladder recurrence than those with single tumors.
In a study, 8.8% of clinically relevant prostate cancers detected by systematic biopsy were missed by MRI-targeted biopsy.
Less intensive PSA screening in men with low PSA levels can substantially reduce unnecessary testing, according to investigators.
In a study, patients with upper tract urothelial carcinoma and pathologic vascular invasion who received adjuvant chemotherapy had significantly longer overall survival than those who did not receive adjuvant chemotherapy.
Type of surgical approach to radical prostatectomy—robot-assisted vs open procedure—is not associated with a patient’s intermediate-term decision regret, according to a recent study.
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
Survival of patients with intermediate-risk metastatic renal cell carcinoma varied according to the number of IMDC or MSKCC risk factors.
Dual immunotherapy appears to have clinical efficacy beyond the first-line setting in patients with metastatic renal cell carcinoma with brain metastases.
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.
